A Prospective, 24-Month Evaluation Of Subjects With Mild To Moderate Open-Angle-Glaucoma Treated With The Omni® Surgical System As Standalone Procedure
Published 2022 - 40th Congress of the ESCRS
Reference: PO375 | Type: Free paper | DOI: 10.82333/6sbz-xd96
Authors: Claudia Cosma 1 , Karsten Klabe* 1
1Internationale Innovative Ophthalmochirurgie,Düsseldorf,Germany
Purpose
The OMNI® Surgical System (Sight Sciences) is indicated for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with open-angle-glaucoma (OAG). The system addresses various mechanisms to reduce the resistance within the conventional outflow pathway in subjects with OAG: trabecular meshwork, Schlemm´s Canal and collector channels.
Here we report the safety and efficacy of the OMNI® Surgical System in patients with OAG treated in a stand-alone procedure in our practice. The objective was to determine the proportion of patients in whom intraocular pressure (IOP) was reduced by at least 20% and the proportion of patients who required less IOP-lowering medication up to 24 months after surgery.
Here we report the safety and efficacy of the OMNI® Surgical System in patients with OAG treated in a stand-alone procedure in our practice. The objective was to determine the proportion of patients in whom intraocular pressure (IOP) was reduced by at least 20% and the proportion of patients who required less IOP-lowering medication up to 24 months after surgery.
Setting
All patients were treated and observed at Breyer Kaymak Klabe Augenchirurgie Düsseldorf, Germany.
Methods
The clinical observation included 38 eyes from 26 patients with OAG treated with the OMNI® Surgical System. We routinely performed the following examinations pre- and postoperatively: IOP, subjective refraction, best corrected visual acuity (BCVA), visual field pachymetry (Humphrey; Zeiss) and slit lamp examinations. Follow-up visits were done on day 1, week 1 and months 1, 3, 6, 12, 18 and 24 after surgery.
Results
26 patients were treated with the OMNI® Surgical System. 26% of patients were pseudophakic, and the mean age at surgery was 66±6 years. All patients were followed up for 12 months, and currently 10 patients (15 eyes) have been followed up for up to 24 months.
Preoperatively, IOP was 24.6±3.0 mmHg. At 12 and 24 months after surgery, IOP decreased to 14.5±1.7 mmHg and 14.2±2.0 mmHg. A reduction in IOP of at least 20% was achieved in 92% or currently 100% of treated eyes. The mean number of IOP-lowering medication was reduced from 1.9±0.7 to 0.4±0.6 and 0.6±0.7. BCVA and visual field showed no significant changes.
The complication rate was low and showed only minor complications as hyphema. No second surgery was needed over 24 months.
Preoperatively, IOP was 24.6±3.0 mmHg. At 12 and 24 months after surgery, IOP decreased to 14.5±1.7 mmHg and 14.2±2.0 mmHg. A reduction in IOP of at least 20% was achieved in 92% or currently 100% of treated eyes. The mean number of IOP-lowering medication was reduced from 1.9±0.7 to 0.4±0.6 and 0.6±0.7. BCVA and visual field showed no significant changes.
The complication rate was low and showed only minor complications as hyphema. No second surgery was needed over 24 months.
Conclusions
The treatment with OMNI® Surgical System is a safe and predictable surgical approach to lower IOP in patients with OAG. Current 2-year-data showed promising results, but more data needed.